Body mass index, hormone replacement therapy, and endometrial cancer risk: A meta-analysis

Cancer Epidemiology Biomarkers and Prevention

Volumn 19, Issue 12, 2010, Pages 3119-3130

  Crosbie, Emma J ^a   Zwahlen, Marcel ^b   Kitchener, Henry C ^a   Egger, Matthias ^b   Renehan, Andrew G ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b UNIVERSITY OF BERN   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BODY MASS; CANCER RISK; ENDOMETRIUM CANCER; HISTOLOGY; HORMONE SUBSTITUTION; HUMAN; MENOPAUSE; META ANALYSIS; PRIORITY JOURNAL; RISK FACTOR; SYSTEMATIC REVIEW;

BODY MASS INDEX; COHORT STUDIES; ENDOMETRIAL NEOPLASMS; FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; RISK FACTORS;

EID: 78650363503     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-10-0832     Document Type: Article

References (82)

1. Amant F, Moerman P, Neven P, Timmerman D, Van Limbergen E, Vergote I. Endometrial cancer. Lancet 2005;366:491-505.
2. World Cancer Reserach Fund. Food, Nutrition, Physical Activity, and the Prevention of Cancer: A Global Perspective. 2nd ed. Washington, DC: American Institute for Cancer Research; 2007.
3. Renehan A, Tyson M, Egger M, Heller RF, Zwahlen M. Body mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet 2008;371:569-78.
4. Kaaks R, Lukanova A, Kurzer MS. Obesity, endogenous hormones, and endometrial cancer risk: A synthetic review. Cancer Epidemiology Biomarkers and Prevention. 2002;11:1531-43.
5. Calle EE, Kaaks R. Overweight, obesity and cancer: Epidemiological evidence and proposed mechanisms. Nat Rev Cancer 2004;4: 579-91.
6. Emons G, Fleckenstein G, Hinney B, Huschmand A, Heyl W. Hormonal interactions in endometrial cancer. Endocr Relat Cancer 2000;7:227-42.
7. Sherman ME. Theories of endometrial carcinogenesis: a multidisciplinary approach. Mod Pathol. 2000;13:295-308.
8. Bokhman JV. Two pathogenetic types of endometrial carcinoma. Gynecol Oncol 1983;15:10-7.
9. Bergstrom A, Pisani P, Tenet V, Wolk A, Adami HO. Overweight as an avoidable cause of cancer in Europe. Int J Cancer 2001;91:421-30.
10. Bianchini F, Kaaks R, Vainio H. Overweight, obesity, and cancer risk. Lancet Oncol 2002;3:565-74.
11. IARC. International Agency for Research in Cancer. Weight control and physical activity. eds.Vainio H, Bianchini F. Lyon: IARC Press; 2002.
12. Setiawan VW, Pike MC, Kolonel LN, Nomura AM, Goodman MT, Henderson BE. Racial/ethnic differences in endometrial cancer risk: the multiethnic cohort study. Am J Epidemiol 2007;165:262-70.
13. World Health Organisation. BMI classification . Available from: http:// www.who.int/bmi/index.jsp?introPage=intro-3.html. Accessed 1 May 2010.
14. Renehan AG, Soerjomataram I, Tyson M, Egger M, Zwahlen M, Coebergh JW, et al. Incident cancer burden attributable to excess body mass index in 30 European countries. Int J Cancer 2010;126:692-702.
15. Orsini N, Bellocco R, Greenland S. Generalized least squares for trend estimation of summarized dose-response data. Stata J 2006;6:40-57.
16. Thompson SG, Higgins JP. How should meta-regression analyses be undertaken and interpreted?Stat Med 2002;21:1559-73.
17. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327:557-60.
18. Tobias A. sbe26: Assessing the influence of a single study in metaanalysis. Stata Tech Bull 1999;47:15-7.
19. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315: 629-34.
20. Baanders-van Halewijn EA, Poortman J. A case-control study of endometrial cancer within a cohort. Maturitas 1985;7:69-76.
21. Tornberg SA, Carstensen JM. Relationship between Quetelet's index and cancer of breast and female genital tract in 47,000 women followed for 25 years. Br J Cancer 1994;69:358-61.
22. Tulinius H, Sigfusson N, Sigvaldason H, Bjarnadottir K, Tryggvadottir L. Risk factors for malignant diseases: A cohort study on a population of 22,946 Icelanders. Cancer Epidemiol Biomarkers Prev 1997;6:863-73.
23. Bernstein L, Deapen D, Cerhan JR, Schwartz SM, Liff J, McGann-Maloney E, et al. Tamoxifen therapy for breast cancer and endometrial cancer risk. J Natl Cancer Inst. 1999;91:1654-62. (Pubitemid 29479933)
24. Olson JE, Sellers TA, Anderson KE, Folsom AR. Does a family history of cancer increase the risk for postmenopausal endometrial carcinoma? A prospective cohort study and a nested case-control family study of older women. Cancer 1999;85:2444-9.
25. Furberg AS, Thune I. Metabolic abnormalities (hypertension, hyperglycemia and overweight), lifestyle (high energy intake and physical inactivity) and endometrial cancer risk in a Norwegian cohort. Int J Cancer. 2003;104:669-76. (Pubitemid 36418502)
26. Schouten LJ, Goldbohm RA, van den Brandt PA. Anthropometry, physical activity, and endometrial cancer risk: results from the Netherlands Cohort Study. J National Cancer Inst 2004;96:1635-8.
27. Kuriyama S, Tsubono Y, Hozawa A, Shimazu T, Suzuki Y, Koizumi Y, et al. Obesity and risk of cancer in Japan. Int J Cancer 2005;113:148-57.
28. Lacey JV Jr., Brinton LA, Lubin JH, Sherman ME, Schatzkin A, Schairer C. Endometrial carcinoma risks among menopausal estrogen plus progestin and unopposed estrogen users in a cohort of postmenopausal women. Cancer Epidemiol Biomarkers Prev 2005; 14:1724-31. (Pubitemid 40995086)
29. Rapp K, Schroeder J, Klenk J, Stoehr S, Ulmer H, Concin H, et al. Obesity and incidence of cancer: A large cohort study of over 145,000 adults in Austria. Br J Cancer 2005;93:1062-7.
30. Silvera SAN, Rohan TE, Jain M, Terry PD, Howe GR, Miller AB. Glycaemic index, glycaemic load and risk of endometrial cancer: a prospective cohort study. Public Health Nutr 2005;8:912-9.
31. Bjorge T, Engeland A, Tretli S, Weiderpass E. Body size in relation to cancer of the uterine corpus in 1 million Norwegian women. Int J Cancer 2006;120:373-83.
32. Lukanova A, Björ O, Kaaks R, Lenner P, Lindahl B, Hallmans G, et al. Body mass index and cancer: Results from the Northern Sweden Health and Disease Cohort. Int J Cancer2006;118:458-66.
33. Chang SC, Lacey JV Jr., Brinton LA, Hartge P, Adams K, Mouw T, et al. Lifetime weight history and endometrial cancer risk by type of menopausal hormone use in the NIH-AARP diet and health study. Cancer Epidemiol Biomarkers Prev 2007;16:723-30. (Pubitemid 46650574)
34. Friedenreich C, Cust A, Lahmann PH, Steindorf K, Boutron-Ruault MC, Clavel-Chapelon F, et al. Anthropometric factors and risk of endometrial cancer: The European prospective investigation into cancer and nutrition. Cancer Causes Control 2007;18:399-413. (Pubitemid 46434795)
35. LarssonSC, Friberg E,Wolk A.Carbohydrate intake, glycemic index and glycemic load in relation to risk of endometrial cancer: A prospective study of Swedish women. Int J Cancer 2007;120:1103-7.
36. Lundqvist E, Kaprio J, Verkasalo PK, Pukkala E, Koskenvuo M, Soderberg KC, et al. Co-twin control and cohort analyses of body mass index and height in relation to breast, prostate, ovarian, corpus uteri, colon and rectal cancer among Swedish and Finnish twins. Int J Cancer 2007;121:810-8.
37. Reeves GK, Pirie K, Beral V, Green J, Spencer E, Bull D. Cancer incidence and mortality in relation to body mass index in the Million Women Study: a cohort study. BMJ 2007;335:1134-45. (Pubitemid 350247286)
38. Lindemann K, Vatten LJ, Ellstrom-Engh M, Eskild A. Body mass, diabetes and smoking, and endometrial cancer risk: a follow-up study. Br J Cancer 2008;98:1582-5. (Pubitemid 351652323)
39. McCullough ML, Patel AV, Patel R, Rodriguez C, Feigelson HS, Bandera EV, et al. Body mass and endometrial cancer risk by hormone replacement therapy and cancer subtype. Cancer Epidemiol Biomarkers Prev 2008;17:73-9.
40. Song YM, Sung J, Ha M. Obesity and risk of cancer in postmenopausal Korean women. J Clin Oncol. 2008;26:3395-402.
41. Conroy MB, Sattelmair JR, Cook NR, Manson JE, Buring JE, Lee IM. Physical activity, adiposity, and risk of endometrial cancer. Cancer Causes Control 2009;20:1107-15.
42. Lindemann K, Vatten LJ, Ellstrom-Engh M, Eskild A. Serum lipids and endometrial cancer risk: results from the HUNT-II study. Int J Cancer 2009;124:2938-41.
43. Tretli S, Magnus K. Height and weight in relation to uterine corpus cancer morbidity and mortality. A follow-up study of 570,000 women in Norway. Int J Cancer 1990;46:165-72.
44. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 2003;348:1625-38.
45. Folsom AR, Kaye SA, Potter JD, Prineas RJ. Association of incident carcinoma of the endometrium with body weight and fat distribution in older women: early findings of the Iowa Women's Health Study. Cancer Res 1989;49:6828-31.
46. Jonsson F, Wolk A, Pedersen NL, Lichtenstein P, Terry P, Ahlbom A, et al. Obesity and hormone-dependent tumors: cohort and co-twin control studies based on the Swedish Twin Registry. Int J Cancer 2003;106:594-9.
47. Patel AV, Feigelson HS, Talbot JT, McCullough ML, Rodriguez C, Patel RC, et al. The role of body weight in the relationship between physical activity and endometrial cancer: results from a large cohort of US women. Int J Cancer 2008;123:1877-82.
48. Anderson KE, Anderson E, Mink PJ, Hong CP, Kushi LH, Sellers TA, et al. Diabetes and endometrial cancer in the Iowa women's health study. Cancer Epidemiol Biomarkers Prev 2001;10:611-6.
49. Jain MG, Rohan TE, Howe GR, Miller AB. A cohort study of nutritional factors and endometrial cancer. Eur J Epidemiol 2000;16: 899-905. (Pubitemid 32298157)
50. Moller H, Mellemgaard A, Lindvig K, Olsen JH. Obesity and cancer risk: a Danish record-linkage study. Eur J Cancer 1994;30A:344-50. (Pubitemid 24152476)
51. Wolk A, Gridley G, Svensson M, Nyren O, McLaughlin JK, Fraumeni JF, et al. A prospective study of obesity and cancer risk (Sweden). Cancer Causes Control 2001;12:13-21. (Pubitemid 32125897)
52. Beral V, Bull D, Reeves G. Endometrial cancer and hormone-replacement therapy in the Million Women Study. Lancet 2005;365: 1543-51.
53. Lindemann K, Vatten LJ, Ellstrom-Engh M, Eskild A. The impact of BMI on subgroups of uterine cancer. Br J Cancer 2009;101:534-6.
54. Bjorge T, Stocks T, Lukanova A, Tretli S, Selmer R, Manjer J, et al. Metabolic syndrome and endometrial carcinoma. Am J Epidemiol 2010;171:892-902.
55. Egger M, Schneider M, Davey Smith G. Spurious precision? Meta-analysis of observational studies. BMJ 1998;316:140-4.
56. Schlesselman JJ. Case-Control Studies. Design, Conduct, Analysis. New York: Oxford University Press; 1982.
57. Kuczmarski MF, Kuczmarski RJ, Najjar M. Effects of age on validity of self-reported height, weight, and body mass index: findings from the Third National Health and Nutrition Examination Survey, 1988-1994. J Am Diet Assoc 2001;101:28-34; quiz 5-6.
58. Tanko LB, Christiansen C. An update on the antiestrogenic effect of smoking: a literature review with implications for researchers and practitioners. Menopause 2004;11:104-9.
59. Al-Zoughool M, Dossus L, Kaaks R, Clavel-Chapelon F, Tjonneland A, Olsen A, et al. Risk of endometrial cancer in relationship to cigarette smoking: results from the EPIC study. Int J Cancer 2007;121:2741-7.
60. Newcomer LM, Newcomb PA, Trentham-Dietz A, Storer BE. Hormonal risk factors for endometrial cancer: modification by cigarette smoking (United States). Cancer Causes Control 2001;12: 829-35.
61. Riley RD, Simmonds MC, Look MP. Evidence synthesis combining individual patient data and aggregate data: a systematic review identified current practice and possible methods. J Clin Epidemiol 2007;60:431-9.
62. Simmonds MC, Higgins JP, Stewart LA, Tierney JF, Clarke MJ, Thompson SG. Meta-analysis of individual patient data from randomized trials: a review of methods used in practice. Clin Trials. 2005;2:209-17.
63. La Vecchia C, Franceschi S, Gallus G, Decarli A, Colombo E, Mangioni C, et al. Oestrogens and obesity as risk factors for endometrial cancer in Italy. Int J Epidemiol 1982;11:120-6.
64. Levi F, La Vecchia C, Gulie C, Franceschi S, Negri E. Oestrogen replacement treatment and the risk of endometrial cancer: an assessment of the role of covariates. Eur J Cancer 1993;29A:1445-9.
65. Grady D, Gebretsadik T, Kerlikowske K, Ernster V, Petitti D. Hormone replacement therapy and endometrial cancer risk: a meta-analysis. Obstet Gynecol. 1995;85:304-13.
66. International Agency for Research on Cancer. Hormonal contraception and post-menopausal hormonal therapy: IARC Monographs on the Evaluation of Carcinogenic Risks to Hormones. Lyon: International Agency for Research on Cancer; 1999.
67. Huber JC, Bentz EK, Ott J, Tempfer CB. Non-contraceptive benefits of oral contraceptives. Expert Opin Pharmacother 2008;9:2317-25.
68. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005;365:1687-717.
69. Renehan AG. Hormone, growth factors and tumor growth. In:Hay ID, Wass JAH, editors. Clinical Endocrine Oncology. Oxford: Oxford University Press; 2008.
70. Effects of hormone replacement therapy on endometrial histology in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial. JAMA 1996;275:370-5.
71. Schiff R, Massarweh SA, Shou J, Bharwani L, Mohsin SK, Osborne CK. Cross-talk between estrogen receptor and growth factor pathways as a molecular target for overcoming endocrine resistance. Clin Cancer Res 2004;10:331S-6S.
72. Lukanova A, Zeleniuch-Jacquotte A, Lundin E, Micheli A, Arslan AA, Rinaldi S, et al. Prediagnostic levels of C-peptide, IGF-I, IGFBP -1, -2 and -3 and risk of endometrial cancer. Int J Cancer 2004;108:262-8.
73. Cust AE, Allen NE, Rinaldi S, Dossus L, Friedenreich C, Olsen A, et al. Serum levels of C-peptide, IGFBP-1 and IGFBP-2 and endometrial cancer risk; results from the European prospective investigation into cancer and nutrition. Int J Cancer 2007;120:2656-64.
74. Cong L, Gasser J, Zhao J, Yang B, Li F, Zhao AZ. Human adiponectin inhibits cell growth and induces apoptosis in human endometrial carcinoma cells, HEC-1-A and RL95 2. Endocr Relat Cancer 2007;14:713-20.
75. Soliman PT, Wu D, Tortolero-Luna G, Schmeler KM, Slomovitz BM, Bray MS, et al. Association between adiponectin, insulin resistance, and endometrial cancer. Cancer 2006;106:2376-81.
76. Cust AE, Kaaks R, Friedenreich C, Bonnet F, Laville M, Lukanova A, et al. Plasma adiponectin levels and endometrial cancer risk in pre- and postmenopausal women. J Clin Endocrinol Metab 2007;92:255-63.
77. Petridou E, Belechri M, Dessypris N, Koukoulomatis P, Diakomanolis E, Spanos E, et al. Leptin and body mass index in relation to endometrial cancer risk. Ann Nutr Metab 2002;46:147-51.
78. Cymbaluk A, Chudecka-Glaz A, Rzepka-Gorska I. Leptin levels in serum depending on Body Mass Index in patients with endometrial hyperplasia and cancer. Eur J Obstet Gynecol Reprod Biol 2008;136:74-7.
79. Key TJ, Appleby PN, Reeves GK, Roddam A, Dorgan JF, Longcope C, et al. Body mass index, serum sex hormones, and breast cancer risk in postmenopausal women. J Natl Cancer Inst 2003;95:1218-26.
80. Jensen J, Christiansen C, Rodbro P. Cigarette smoking, serum estrogens, and bone loss during hormone-replacement therapy early after menopause. N Engl J Med 1985;313:973-5.
81. Beresford SA, Weiss NS, Voigt LF, McKnight B. Risk of endometrial cancer in relation to use of oestrogen combined with cyclic progestagen therapy in postmenopausal women. Lancet 1997;349:458-61.
82. Renehan AG. Bariatric surgery, weight reduction and cancer prevention. Lancet Oncol 2009;10:640-1.